Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 12, 2007, Pages 2266-2272

  Chang, Full Young ^a,b   Lu, Ching Liang ^a   Chen, Chih Yen ^a   Luo, Jiing Chyuan ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Abdominal bloating; Diosmectite; Functional gastrointestinal disorder; Irritable bowel syndrome; Rome criteria

Indexed keywords

PLACEBO; SILICON DIOXIDE;

ABDOMINAL PAIN; ACUTE APPENDICITIS; ADULT; AGED; ARTICLE; BLOATING; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTESTINE MOTILITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALAISE; MALE; MENSTRUATION DISORDER; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; VOMITING;

EID: 36348929285     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04895.x     Document Type: Article

References (46)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 130 : 1337 90.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
4. Lacy BE, Lee RD. Irritable bowel syndrome: a syndrome in evolution. J. Clin. Gastrotenterol. 2005 39 : S230 42.
5. Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment. Pharmacol. Ther. 2004 190 : 1217 14.
6. Chang FY, Lu CL. Irritable bowel syndrome in the 21st century: perspectives from Asia or Southeast Asia. J. Gastroenterol. Hepatol 2007 22 : 4 12.
7. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002 360 : 555 64.
8. Lu CL, Chen CY, Lang HC et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment. Pharmachol. Ther. 2003 18 : 1159 69.
9. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br. Med. J. 1978 2 : 653 4.
10. Lu CL, Chen CY, Chang FY, Lee SD. The characteristics of small bowel motility in irritable bowel syndrome patients and normal humans: an Oriental study. Clin. Sci. 1998 95 : 165 9.
11. Sinhamahapatra P, Saha SP, Chowdhury A, Chakrabarti SK, Ghosh A, Maiti B. Visceral afferent hypersensitivity in irritable bowel syndrome-evaluation by cerebral evoked potential after rectal stimulation. Am. J. Gastroenterol. 2001 96 : 2150 7.
12. Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig. Dis. Sci. 2002 47 : 1716 22.
13. Lee CT, Chuang TY, Lu CL, Chen CY, Chang FY, Lee SD. Abnormal vagal cholinergic function and psychological behaviors in irritable bowel syndrome patients with predominant bowel symptoms: a hospital-based Oriental Study. Dig. Dis. Sci. 1998 43 : 1794 9.
14. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004 53 : 1096 101.
15. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired pot-infectious irritable bowel syndrome. Gut 2003 52 : 523 6.
16. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999 44 : 400 6.
17. Camilleri M, Heading RC, Thompson WG. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2002 16 : 1407 30.
18. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001 48 : 272 82.
19. Drossman DA. What dose the future hold for irritable bowel syndrome and the functional gastrointestinal disorders? J. Clin. Gastroenterol. 2005 39 : S251 6.
20. Lembo TJ, Fink RN. Clinical assessment of irritable bowel syndrome. J. Clin. Gastroenterol. 2002 35 : S31 6.
21. Bueno L. Gastrointestinal pharmacology: irritable bowel syndrome. Curr. Opin. Pharmacol. 2005 5 : 583 8.
22. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine. JAMA 1998 280 : 1585 9.
23. Bensoussan A. Establishing evidence for Chinese medicine: a case example of irritable bowel syndrome. Chin. Med. J. (Taipei) 2001 64 : 487 92.
24. Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome, analysis of the literature. J. Clin. Gastroenterol. 2005 39 : S243 6.
25. Madkour AA, Madina EM, El-Azouni OE, Amer MA, El-Walili TM, Abbass T. Smectite in acute diarrhea in children: a double-blind placebo-controlled trial. J. Paediatr. Gastroenterol. Nutr. 1993 17 : 176 81.
26. Legré M, Andreotti D. Double-blind comparative study on dioctahedral smectite and actapulgite in treatment of colonopathies. Gaz. Med. Fr. 1980 87 : 1 3.
27. Leber W. A new suspension form of smectite (liquid diasorb) for the treatment of acute diarrhea: a randomized comparative study. Pharmatherapeutica 1988 5 : 256 60.
28. Van Maercke Y, Mallend M. Clinical trial to compare the efficacy and tolerance of Smecta (intestinal topic consisting of dioctahedral smectite) and loperamide in the treatment of acute diarrhea in adults. TIJDSCHR Gastroenterology 1987 17 : 367 9.
29. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988 95 : 232 41.
30. Pattee PL, Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992 44 : 200 6.
31. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. 2000 133 : 136 47.
32. Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006 130 : 1435 46.
33. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil. 2005 17 : 643 53.
34. Droy-Lefaix MT, Drouet Y, Schatz B. Sodium glycodeoxycholate and spinability of gastrointestinal mucus. protective effect of smectite. Gastroenterology 1985 88 : 1369A.
35. Droy-Lefaix MT, Drouet Y, Geraud G. Protective effect of smectite on gastrointestinal biliary salts rat damage. Gastronterol. Int. 1988 1 (Suppl. 1 1076.
36. Moré J, Bénazet J, Fioramonti J, Droy-Lefaix MT. Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study. Histochem. J. 1987 19 : 665 70.
37. Leonard AJ, Droy-Lefaix MT, Allen A. Pepsin damage in rat stomach in vivo: effect of smectite and dimethyl prostaglandin E2. Gastroenterology 1993 104 : A132.
38. Mahraoui L, Heyman M, Plique O, Droy-Lefaix MT, Desjeux JF. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. Gut 1997 40 : 339 43.
39. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000 47 : 804 11.
40. Collins SM, Barbara G. East meets west: infection, nerves, and mast cells in irritable bowel syndrome. Gut 2004 53 : 1068 9.
41. Opriu AL, Diculescu M, Lov A et al. Enterocyte covering agent versus intestinal motility inhibitor in the irritable bowel. Gut 1996 39 (Suppl. A34.
42. Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Aliment. Pharmacol. Ther. 2005 21 : 435 44.
43. Dapoigny M, Giral P, Plique O. Visible abdominal swelling and functional disorders of the intestine (FDI): should medical treatment be given along with dietary advice? Gut 1995 37 : 1366.
44. De Sola Pool N, Loehle K, Radzik AJ, Kinsley J. A comparison of nonsystemic and systemic antidiarrheal agents in the treatment of acute non-specific diarrhea in adults. Today's Ther. Trends 1987 5 : 31 8.
45. Wingate D, Phillip SF, Lewis SJ et al. Guidelines for adults on self-medication for the treatment of acute diarrhea. Aliment. Pharmacol. Ther. 2001 15 : 773 82.
46. Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006 130 : 1538 51.